Hikma’s Vascepa Launch Strategy ‘Can Cause Market Confusion’
Pro-Amarin Investor Makes Hikma Claim
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
